Skip to main content
Premium Trial:

Request an Annual Quote

Tm Biosciences' Q2 Revenues Climb 55 Percent Though Loss Widens

NEW YORK (GenomeWeb News) – Tm Bioscience today reported that net losses for the second quarter increased despite a 55-percent surge in revenues.
 
The company reported $3 million in revenues for the quarter ended June 30, up from $2 million during the same quarter a year ago.
 
Product sales for the second quarterclimbed 80 percent to $2.9 million from $1.6 million in second quarter 2005, the company said. It added that sales of Tag-It CF70 reagents and increased demand from Genzyme drove the growth.
 
Tm Bioscience’s R&D expenses for the quarter remained essentially flat at $1.1 million.
 
The company’s quarterly net loss widened 26 percent to $4.6 million from $3.7 million in the year-ago period.
 
As of June 30, Tm Bioscience had $2.8 million in cash, cash equivalents, and short-term investments.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.